180 Life Sciences Raises $156M for ETH Purchase

180 Life Sciences Corp., now recognized as “ETHZilla,” announced a successful raise of $156 million via convertible notes. This financing will enhance their Ethereum treasury strategy, marking a significant shift in their operational focus.

The company, led by Executive Chairman McAndrew Rudisill, aims to bolster its Ethereum holdings. This decision underscores a strategic pivot, with proceeds from the convertible notes primarily directed towards purchasing more ETH.

Immediate impacts include potential market fluctuations as the company aggressively enters the Ethereum space. The significant capital infusion reflects a robust commitment, potentially affecting other investors’ perceptions of crypto treasury strategies.

Financially, the move could induce volatility in 180 Life Sciences Corp.’s stock, leveraging its financial structure to impact its market valuation directly. Such strategies often attract speculative interest and investor scrutiny.

The company’s decision has attracted notable investors, with Peter Thiel’s group holding a 7.5% stake. Such backing could amplify industry attention on Ethereum acquisition strategies.

Projected outcomes include increased transparency demands as the company plans regular updates on its ETH holdings. Historical parallels suggest potential increases in stock volatility, while industry analysts may view this pivot as a bellwether for similar corporate strategies.

“The Convertible Note offering further strengthens our balance sheet and will be used to increase our ETH holdings.” — McAndrew Rudisill, Executive Chairman, 180 Life Sciences Corp. Source